CN114773348B - 一种咪达唑仑的制备方法及其中间体 - Google Patents
一种咪达唑仑的制备方法及其中间体 Download PDFInfo
- Publication number
- CN114773348B CN114773348B CN202210576934.4A CN202210576934A CN114773348B CN 114773348 B CN114773348 B CN 114773348B CN 202210576934 A CN202210576934 A CN 202210576934A CN 114773348 B CN114773348 B CN 114773348B
- Authority
- CN
- China
- Prior art keywords
- acid
- reaction
- alcohol
- midazolam
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 229960003793 midazolam Drugs 0.000 title claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 150000002466 imines Chemical class 0.000 claims abstract description 16
- 150000001298 alcohols Chemical class 0.000 claims abstract description 11
- 238000006268 reductive amination reaction Methods 0.000 claims abstract description 6
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims abstract 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 65
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 44
- 230000002829 reductive effect Effects 0.000 claims description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 25
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 24
- 239000007810 chemical reaction solvent Substances 0.000 claims description 24
- 239000003638 chemical reducing agent Substances 0.000 claims description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 239000007848 Bronsted acid Substances 0.000 claims description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- -1 sodium triacetoxyborohydride Chemical compound 0.000 claims description 18
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 16
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 230000009471 action Effects 0.000 claims description 14
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 claims description 14
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 11
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 10
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 150000003573 thiols Chemical class 0.000 claims description 10
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 10
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 claims description 9
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 9
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 8
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
- 239000007800 oxidant agent Substances 0.000 claims description 8
- 230000001590 oxidative effect Effects 0.000 claims description 8
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 8
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 8
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 8
- 239000008096 xylene Substances 0.000 claims description 8
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 claims description 7
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 239000012279 sodium borohydride Substances 0.000 claims description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 7
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 claims description 6
- YGKHJWTVMIMEPQ-UHFFFAOYSA-N 1,2-propanedithiol Chemical compound CC(S)CS YGKHJWTVMIMEPQ-UHFFFAOYSA-N 0.000 claims description 6
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 6
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 6
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 6
- QNNVICQPXUUBSN-UHFFFAOYSA-N 2-sulfanylpropan-1-ol Chemical compound CC(S)CO QNNVICQPXUUBSN-UHFFFAOYSA-N 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- 239000003341 Bronsted base Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- RSBQFKJVGZVGFM-UHFFFAOYSA-N 1,3-diaminopropan-2-one Chemical compound NCC(=O)CN RSBQFKJVGZVGFM-UHFFFAOYSA-N 0.000 claims 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 239000013067 intermediate product Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 88
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 18
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 239000007858 starting material Substances 0.000 abstract description 7
- 239000012535 impurity Substances 0.000 abstract description 6
- 238000007363 ring formation reaction Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 231100000024 genotoxic Toxicity 0.000 abstract description 5
- 230000001738 genotoxic effect Effects 0.000 abstract description 5
- 230000009467 reduction Effects 0.000 abstract description 4
- 238000006722 reduction reaction Methods 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 238000010511 deprotection reaction Methods 0.000 abstract 1
- 238000005755 formation reaction Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000012074 organic phase Substances 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000007788 liquid Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 239000008213 purified water Substances 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 8
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000003651 drinking water Substances 0.000 description 7
- 235000020188 drinking water Nutrition 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000011976 maleic acid Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000003944 tolyl group Chemical group 0.000 description 4
- XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 description 3
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960004653 midazolam maleate Drugs 0.000 description 3
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 3
- 229940078552 o-xylene Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000014666 liquid concentrate Nutrition 0.000 description 2
- PLYSCVSCYOQVRP-UHFFFAOYSA-N midazolam hydrochloride Chemical compound Cl.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F PLYSCVSCYOQVRP-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000009935 nitrosation Effects 0.000 description 2
- 238000007034 nitrosation reaction Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000004537 pulping Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 238000005915 ammonolysis reaction Methods 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960002853 midazolam hydrochloride Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000005839 oxidative dehydrogenation reaction Methods 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/06—Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明属于药物化学制备领域,公开了一种咪达唑仑的制备方法及其中间体M2。本发明所提供的制备方法为:以SM1作为起始物料,与醇、硫醇或巯基取代的醇进行反应,得到中间体M2经还原胺化或先形成亚胺再还原,在酸性条件下脱保护基,原位碱化关环反应后,再与原乙酸酯反应,最后氧化得到咪达唑仑。本发明的制备方法具有步骤简短、收率高、反应条件温和、后处理简便、避免了传统路线涉及的危险反应、危险试剂、管制试剂和基因毒性杂质,因此操作及产品的安全性较高、有利于工业化大规模生产。
Description
技术领域
本发明涉及药物化学制备领域,具体涉及一种咪达唑仑的制备方法及其中间体。
背景技术
苯并二氮杂类药物是一类具有很高药理活性和广泛应用前景的药物,其主要通过激动性地结合中枢神经系统内的γ-氨基丁酸受体(GABAA)发挥介导作用,典型的药理学性质有:抗焦虑、镇静催眠、抗惊厥、中枢性肌肉松弛和术前麻醉等。
咪达唑仑由罗氏公司开发,于1998年在美国首次获批上市,其主要剂型包括片剂、注射剂、口服溶剂等,对应原料药有游离碱、马来酸盐、盐酸盐等不同成药方式。在我国属于国家管制的第二类精神药品,主要适应症用于儿科患者(6个月-16岁)在诊断、治疗、内镜操作或麻醉诱导前的镇静、抗焦虑和顺行性遗忘。咪达唑仑化学名为1-甲基-8-氯-6-(2-氟苯基) -4H-咪唑并[1,5-a][1,4]苯并二氮杂具有典型的苯并二氮杂/>母核结构,是一种浅黄色结晶性固体,CAS号59467-96-8。其中,盐酸咪达唑仑的化学结构式如下所示:
目前关于咪达唑仑的合成路线较多,其中路线一(Walser A,Thomas Flynn,MasonC,et al.J Org Chem,1978,43(5):936-944.)公开了以化合物2做为起始原料,与氯乙酰氯反应生成中间体1,氨解、关环得到中间体2,在四氯化钛存在的情况下与甲胺缩合,亚硝化得到4,在强碱的情况下与硝基甲烷反应产生5,雷尼镍催化氢化、马来酸成盐得到中间体6,与原乙酸三乙酯环合、二氧化锰氧化脱氢得到咪达唑仑游离碱。但化合物2价格较高,其合成仍需以SM1 作为起始原料,该路线总计8步反应,文献报道总收率约6.7%,为目前的主流的放大合成路线,路线一合成如Scheme 1所示。
但该路线中存在如下问题:1)氯乙酰氯为剧毒性管制品、乌洛托品、甲氨气体或甲氨溶液为管制试剂,不仅购买、运输困难,而且操作安全风险高;2)反应路线中存在卤化、氨化、亚硝化、氢化、氧化等多步涉及18种安全风险较高的重点监控反应;3)反应路线中使用了过量的雷尼镍催化剂,工艺放大过程中具有很大的安全隐患;4)路线中使用了亚硝酸钠试剂,反应过程中易于产生亚硝胺类杂质,亚硝胺属于遗传毒性杂质,不利用产品质量的控制,存在一定的质量风险。
路线二(Walser A,Fryer RI.J Heterocycl Chem,1983,20(3):551-558.):化合物1、2、3、 4的合成方法与路线一相同,中间体4在叔丁醇钾的作用下与丙二酸二甲酯反应生成中间体 14,在氢氧化钾作用下发生水解脱羧反应,随后与亚硝酸钠反应生成中间体16,16经雷尼镍催化氢化、原乙酸三甲酯环化、水解、脱羧反应得到咪达唑仑,路线二合成如Scheme 2所示。但整条路线总计11步反应,路线冗长,收率低,成本高,同时也存在路线一的问题。
综上,现有技术合成咪达唑仑目前存在的问题:如步骤繁琐且收率低,反应过程中涉及危险反应、危险试剂和管制试剂较多,不适用于工业化生产;反应过程中也涉及亚硝胺类基因毒性杂质,存在一定的质量风险;因此研究寻找一条步骤短、产品质量安全性可靠、操作简便、生产周期短、设备兼容性好、更适合于工业化大规模生产的路线仍是目前需要解决的问题。
发明内容
为克服上述技术缺陷,本发明目的在于提供一种咪达唑仑的中间体化合物及其制备方法,以及利用该新中间体化合物制备咪达唑仑的新方法。该方法解决了现有技术的反应路线长、收率低以及涉及危险反应、危险试剂、管制试剂和基因毒性杂质问题,实现了步骤短、产品质量安全性可靠、操作简便、生产周期短、设备兼容性好、更适合于工业化大规模生产。
本发明第一方面提供了中间体M2化合物,其结构如下式所示:
其中,所述X,Y分别独立地选自O、S,n取自1-3;R,R’分别独立地选自烷氧羰基或酰基;
进一步地,R,R’分别独立地选自烷氧羰基为甲氧羰基、乙氧羰基或叔丁氧羰基,酰基为三氟乙酰基;
更进一步地,R,R’均为叔丁氧羰基。
本发明第二方面提供了中间体M2的制备方法,包括以下步骤:
1)以SM1作为起始物料,与醇、硫醇或者巯基取代的醇生成中间体M1;
2)在反应溶剂中,M1与SM2先形成亚胺,再在还原剂的作用下还原得到中间体M2;
进一步地,本发明的第1)步中所述醇选自乙二醇或丙二醇,硫醇选自乙二硫醇或丙二硫醇,巯基取代的醇选自2-巯基乙醇或2-巯基丙醇;
进一步地,本发明的第2)步所述反应溶剂为甲苯、二甲苯(邻二甲苯、间二甲苯或对二甲苯中一种或多种)或均三甲苯;
进一步地,本发明的第2)步所述SM2为烷氧羰基或酰基保护的1,3-二胺基丙酮,R,R’分别独立地选自烷氧羰基为甲氧羰基、乙氧羰基或叔丁氧羰基,酰基为三氟乙酰基;
进一步地,本发明的第2)步所述还原剂为三乙酰氧基硼氢化钠、氰基硼氢化钠或硼氢化钠。
本发明第三方面提供了中间体M2的制备方法,包括以下步骤:
1)以SM1作为起始物料,与醇、硫醇或者巯基取代的醇生成中间体M1;
2)在反应溶剂中,M1与SM2在布朗斯特酸催化剂及还原剂的作用下,还原胺化得到M2;
进一步地,本发明的第1)步中所述醇选自乙二醇或丙二醇,硫醇选自乙二硫醇或丙二硫醇,巯基取代的醇选自2-巯基乙醇或2-巯基丙醇;
进一步地,本发明的第2)步所述反应溶剂为1,2-二氯乙烷、二氯甲烷、四氢呋喃、乙腈或甲苯;
进一步地,本发明的第2)步所述SM2为烷氧羰基或酰基保护的1,3-二胺基丙酮,R,R’分别独立地选自烷氧羰基为甲氧羰基、乙氧羰基或叔丁氧羰基,酰基为三氟乙酰基;;
进一步地,本发明的第2)步所述布朗斯特酸选自醋酸、甲酸、三氟乙酸、草酸、浓盐酸、氢溴酸或浓硫酸;
进一步地,本发明的第2)步的还原剂选自三乙酰氧基硼氢化钠、氰基硼氢化钠或硼氢化钠。
本发明第四方面提供具体制备咪达唑仑的工艺,该工艺包括如下步骤:
1)以SM1作为起始物料,与硫醇生成中间体M1;
2)反应溶剂中,M1与SM2先形成亚胺,再在还原剂的作用下还原得到中间体M2;
3)中间体M2在布朗斯特酸及碱的作用下关环得到M3;
4)M3与原乙酸酯试剂经高温环合反应得到M4;
5)M4经氧化得到咪达唑仑;
进一步地,本发明的第1)步所述硫醇为乙二硫醇或丙二硫醇;在本发明的具体实施方案中,硫醇优选为乙二硫醇;
进一步地,本发明的第2)步所述反应溶剂为甲苯、二甲苯(邻二甲苯、间二甲苯或对二甲苯中一种或多种)或均三甲苯,在本发明的具体实施方案中,反应溶剂优选为甲苯;
进一步地,本发明的第2)步所述SM2为烷氧羰基或酰基保护的1,3-二胺基丙酮,R,R’分别独立地选自烷氧羰基为甲氧羰基、乙氧羰基或叔丁氧羰基,酰基为三氟乙酰基,在本发明的具体实施方案中,R,R’均优选为叔丁氧羰基;
进一步地,本发明的第2)步所述还原剂选自三乙酰氧基硼氢化钠、氰基硼氢化钠或硼氢化钠,在本发明的具体实施方案中,还原剂优选为氰基硼氢化钠;
进一步地,本发明第3)步所述碱选自氨水、三乙胺、二异丙基乙胺、三甲胺、二乙胺或二甲胺,在本发明的具体实施方案中,碱优选为氨水;
进一步地,本发明的第3)步所述布朗斯特酸选自三氟乙酸、浓盐酸、氢溴酸、浓硫酸、磷酸或高氯酸,在本发明的具体实施方案中,布朗斯特酸优选为浓盐酸;
进一步地,本发明第4)步所述原乙酸酯试剂选自原乙酸三甲酯或原乙酸三乙酯,在本发明的一些具体实施方案中,原乙酸类酯试剂优选为原乙酸三甲酯;
进一步地,本发明第4)步所述高温为80-130℃;在本发明的具体实施方案中,高温优选为110℃;
进一步地,本发明第4)步的反应溶剂可以根据需要选择合适的溶剂,所述溶剂选自甲苯、苯、二甲苯(邻二甲苯、间二甲苯或对二甲苯中一种或多种)或均三甲苯,在本发明的具体实施方案中,溶剂优选为甲苯;
进一步地,本发明第5)步所述氧化剂选自二氧化锰和二甲基亚砜中一种或两种,在本发明的具体实施方案中,氧化剂优选为混合的二氧化锰和二甲基亚砜;
进一步地,本发明第5)步的反应温度可以根据需要选择合适的温度,反应温度为100-160℃,在本发明的具体实施方案中,反应温度优选为150℃;
进一步地,本发明第5)步的反应溶剂可以根据需要选择合适的溶剂,所述溶剂选自甲苯、二甲苯、均三甲苯、苯或二甲基亚砜,在本发明的具体实施方案中,溶剂优选为二甲基亚砜。
本发明第五方面提供具体制备咪达唑仑的工艺,该工艺包括如下步骤:
1)以SM1作为起始物料,与醇生成中间体M1;
2)在反应溶剂中,M1与SM2在布朗斯特酸催化剂及还原剂的作用下,还原胺化得到M2;
3)中间体M2在布朗斯特酸以及碱的作用下得到M3;
4)M3与原乙酸酯试剂经高温环合反应得到M4;
5)M4经氧化得到咪达唑仑;
进一步地,本发明的第1)步所述醇为乙二醇或丙二醇,在本发明的具体实施方案中,醇优选为乙二醇;
进一步地,本发明的第2)步反应溶剂选自1,2-二氯乙烷、二氯甲烷、四氢呋喃、乙腈或甲苯,在本发明的具体实施方案中,反应溶剂优选为二氯甲烷;
进一步地,本发明的第2)步所述SM2为烷氧羰基或酰基保护的1,3-二胺基丙酮,R,R’分别独立地选自烷氧羰基为甲氧羰基、乙氧羰基或叔丁氧羰基,酰基为三氟乙酰基;在本发明的具体实施方案中,R,R’均优选为叔丁氧羰基;
进一步地,本发明的第2)步的布朗斯特酸选自醋酸、甲酸、三氟乙酸、草酸、盐酸、氢溴酸或硫酸,在本发明的具体实施方案中,布朗斯特酸优选为醋酸;
进一步地,本发明的第2)步所述还原剂选自三乙酰氧基硼氢化钠、氰基硼氢化钠或硼氢化钠,在本发明的具体实施方案中,还原剂优选为三乙酰氧基硼氢化钠;
进一步地,本发明的第3)步所述布朗斯特酸选自三氟乙酸、浓盐酸、氢溴酸、浓硫酸、磷酸或高氯酸,在本发明的具体实施方案中,布朗斯特酸优选为浓盐酸;
进一步地,本发明第3)步所述碱选自氨水、三乙胺、二异丙基乙胺、三甲胺、二乙胺或二甲胺,在本发明的具体实施方案中,碱优选为氨水;
进一步地,本发明第4)步所述原乙酸酯试剂选自原乙酸三甲酯或原乙酸三乙酯;在本发明的具体实施方案中,原乙酸类酯试剂优选为原乙酸三甲酯;
进一步地,本发明第4)步所述高温为80-130℃,在本发明的具体实施方案中,高温优选为110℃;
进一步地,本发明第4)步的反应溶剂可以根据需要选择合适的溶剂,所述溶剂选自甲苯、苯、二甲苯(邻二甲苯、间二甲苯或对二甲苯一种或多种)或均三甲苯,优选地,反应溶剂为甲苯或二甲苯,在本发明的具体实施方案中,溶剂优选为甲苯;
进一步地,本发明第5)步所述氧化剂选自二氧化锰和二甲基亚砜中一种或两种,在本发明的具体实施方案中,氧化剂优选为混合的二氧化锰和二甲基亚砜;
进一步地,本发明第5)步的反应温度可以根据需要选择合适的温度,反应温度为100-160℃,在本发明的具体实施方案中,反应温度优选为150℃;
进一步地,本发明第5)步的反应溶剂可以根据需要选择合适的溶剂,所述溶剂选自甲苯、二甲苯、均三甲苯、苯或二甲基亚砜,在本发明的具体实施方案中,溶剂优选为二甲基亚砜。
发明带来的有益效果有:
1、本发明提供了一种新的中间体M2以及利用该中间体制备咪达唑仑的新方法,该方法具有步骤短,操作简便,易于放大,适合工业化大规模生产,且得到目标产物纯度高、可达 99.92%。
2、本发明整条路线不涉及现有技术提到的危险反应、危险试剂、管制试剂和基因毒性杂质,因此提高了反应及操作的安全性以及产品的安全性,同时减少三废的产生,降低生产成本。
具体实施方式
为使本发明更加容易理解,下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而用于限制本发明的范围,下例实施例中未提及的具体实验方法,通常按常规实验方法进行。本发明中除试剂SM2自制外,使用的试剂均为市售产品。
化合物的结构采用核磁共振(1HNMR)确定。
核磁共振(1HNMR)位移(δ)以百万分之一(ppm)的单位给出;核磁共振(NMR)的测定是用1HNMR仪,测定溶剂为DMSO-d6,内标为四甲基硅烷(TMS),化学位移是以10-6(ppm)作为单位给出。
HPLC谱图的测定采用安捷伦Agilent1260DAD型(或岛津LC-2030)液相色谱仪进行。本申请中,HPLC纯度用以下方法进行:
(1)以十八烷基硅烷键合硅胶为填充剂的色谱柱
(2)检测器:紫外检测器(波长254nm)
(3)流速:每分钟1.0mL
(4)运行时间:梯度洗脱
(5)供试品溶液:临用新制。取本品适量,精密称定,加甲醇溶解并定量稀释制成每1ml中约含1mg的溶液
(6)进样量:10μl,通过自动积分法测定供试品溶液,按峰面积计算供试品中XX的纯度。
制备例:SM2的制备过程:
(1)SM2-1的制备:
在反应釜中加入2.00kg SM2-2,10.0Kg二氯甲烷,开启搅拌,降温至0-5℃,加入9.5kg 二碳酸二叔丁酯,升温至20-30℃条件下反应6-12h,TLC检测反应完成后减压浓缩至无明显液体滴出,加入8.0kg石油醚室温搅拌打浆,离心,于40-55℃条件下干燥6-8h,得中间体 SM2-1为5.93Kg,收率92%。
(2)SM2的制备:
在反应瓶中加入1.64kg草酰氯,4.3kg二氯甲烷,氮气置换三次,降温至-60℃以下,滴加2.02kg DMSO和2.0kg二氯甲烷的混合溶剂,滴毕,再次滴加2.5kg SM2-1和6.0kg二氯甲烷的混和溶液,滴毕,缓慢滴入3.48kg三乙胺,控温-10℃以下反应2-4h,室温反应6-8h。TLC检测反应完成后将反应液加入反应釜中,加入4.0kg饮用水,搅拌,分液。有机相减压浓缩至干。加入5.0kg石油醚升温至40℃打浆,降温至0-5℃析晶2-4h,离心所得固体于40-55℃条件下干燥6-8h,得到起始物料SM2为2.2kg,收率90%。
1HNMR(400MHz,DMSO-d6)δ7.03(t,J=5.9Hz,1H),3.78(d,J=5.9Hz,2H),3.33(s,0H),1.38(s,10H).
下面结合具体实施例,对本发明进行进一步的说明:
实施例1中间体M2的制备
上述路线表示M1与SM2先形成亚胺中间态,再在还原剂的作用下还原制得中间体M2,表1和表2分别是在不同反应条件下制得的M2。
1H NMR(400MHz,DMSO-d6)δ8.02(td,J=8.3,1.8Hz,1H),7.62–7.54(m,1H),7.39(dtd, J=7.7,5.2,2.4Hz,1H),7.26(t,J=7.5Hz,1H),7.14(ddd,J=19.9,10.2,5.2Hz,2H),6.79(d,J=8.9Hz,1H),6.56(t,J=6.0Hz,2H),3.52–3.41(m,2H),3.39–3.34(m,1H),2.81(dt,J=13.0, 6.0Hz,2H),2.64–2.53(m,1H),1.38(s,18H).
表1形成亚胺中间态所用反应溶剂、催化剂、温度的选择
备注:亚胺的还原阶段采用混合溶剂,亚胺反应完成后加入40%体积的甲醇作为反应溶剂。
表2亚胺中间态还原所用反应溶剂、还原剂、还原剂用量的选择
备注:亚胺的还原阶段采用单一溶剂,亚胺反应完成后,反应液减压浓缩至干,加入对应溶剂和还原剂进行反应。
实施例2中间体M2的制备
上述路线表示M1与SM2在布朗斯特酸催化剂及还原剂的作用下,还原胺化制得M2,表3是在不同反应条件下制得的M2。
1HNMR(400MHz,DMSO-d6)δ7.65(t,J=7.6Hz,1H),7.38(tt,J=6.3,3.7Hz,2H),7.13 (dddd,J=32.1,11.5,7.8,1.2Hz,3H),6.95–6.51(m,3H),5.27(d,J=7.3Hz,1H),4.24–3.84(m, 4H),2.84(dq,J=56.1,7.5,7.1Hz,3H),1.99(s,1H),1.38(s,19H)。
表3还原胺化制备M2所用反应溶剂、催化剂、还原剂、还原剂用量的选择
实施例3中间体M2的制备
在反应瓶中加入20g SM1、15.9g乙二硫醇,加入200ml二氯甲烷,通过滴液漏斗缓慢滴入30.4g四氯化钛,滴毕,升温至35±5℃反应,TLC监控反应完成后,缓慢滴入100ml 饮用水淬灭反应,滴毕,产品析出,继续保温搅拌2h,过滤,滤饼于45-55℃条件下干燥4-6h,收料,得到浅黄色固体21.6g的M1,收率82.7%,HPLC纯度96.75%。
1HNMR(400MHz,Methanol-d4)δ8.03(td,J=8.1,1.7Hz,1H),7.49(tt,J=8.3,2.1Hz,2H), 7.42(d,J=8.5Hz,1H),7.32(td,J=7.6,1.2Hz,1H),7.24–7.14(m,1H),7.09(t,J=2.0Hz,1H), 3.80–3.67(m,2H),3.43(td,J=6.4,4.2Hz,2H).
在反应瓶中依次加入150ml甲苯,20g M1,26.6g SM2,0.74g醋酸,升温至剧烈回流,分水反应,反应约16-24h,至TLC检测反应完全,降温至30±10℃,加入无水甲醇60ml,分批缓慢加入17.1g NaBH3CN(4.0eq),反应约1-3h,至TLC检测反应完全。反应液降温至0-10℃,缓慢滴入80.0ml饮用水,过滤,滤饼于45-55℃条件下减压浓缩冷凝管至无大量有机相滴出,加入60g乙酸乙酯萃取,水相用60g乙酸乙酯反萃,合并有机相,浓缩至干得到棕黄色油状物M2,直接用于下一步反应。M2结构鉴定同实施例1的核磁数据一致。
实施例4中间体M2的制备
在2L反应瓶中加入乙二醇600ml(6V),100g SM1(0.40mol),通过恒压低液漏斗滴入三甲基氯硅烷218g(2.0mol,5.0eq.),滴加毕,升温至50-55℃反应约16-24h,TLC (PE/EA=3/1)/HPLC检测至原料残留在约5%以下。将反应液滴加到1.2L饱和碳酸钠水溶液中,加入EA萃取,每次600ml,共三次,合并有机相,饮用水洗涤两次,每次600ml,共两次,有机相浓缩至干,得到125g粗品,加入250ml甲苯,升温至50-60℃打浆,降至10-15℃,搅拌1-2h,过滤,干燥,得到96.5g M1,呈浅黄色固体M1,收率82%,HPLC纯度:94.82%。1HNMR(400MHz,DMSO-d6)δ7.57(td,J=7.9,1.8Hz,1H),7.38(dddd,J=8.1,7.0,5.0,1.9Hz, 1H),7.33(t,J=2.5Hz,1H),7.17(td,J=7.6,1.2Hz,1H),7.11(ddd,J=11.6,8.2,1.1Hz,1H), 7.05(dd,J=8.6,2.6Hz,1H),6.62(d,J=8.6Hz,1H),5.14(s,2H),4.12–3.87(m,4H).
5L反应瓶中依次加入二氯甲烷600ml(10M/M),60g M1(0.2mol,1.0eq),88g SM2(1.5eq),醋酸6.0g,缓慢分批加入三乙酰氧基硼氢化钠173.2g(4.0eq.)反应,反应约6-16h,至TLC检测反应完全,直接用于下一步反应。经分离纯化后可得到M2为浅黄色油状液体。 M2结构鉴定同实施例2的核磁数据一致。
实施例5咪达唑仑的制备
(1)中间体M3的制备
在实施例3得到反应液浓缩物中加入180ml乙腈,18ml饮用水,开启搅拌,加入10.4g 碳酸氢钠、62.8g碘单质,于35-45℃条件下搅拌反应至完成,加入饮用水100ml,亚硫酸钠 25.5g,搅拌1-2h,45-55℃条件下减压浓缩至无明显液体滴出,加入100ml乙酸乙酯萃取两次,合并有机相,减压浓缩至无明显液滴流出,直接用于下一步反应。
在上述反应液中加入甲醇100ml,降温至5±5℃,缓慢滴入浓盐酸48ml,滴毕,升至室温反应16-26h,至TLC检测反应完全。反应体系降温至5±5℃,滴加浓氨水调节pH至>8,加毕,于室温条件下反应2-6h,至TLC检测反应完全。45-55℃条件下减压浓缩冷凝管至无大量有机相滴出,加入100ml乙酸乙酯,分液,水相加100ml乙酸乙酯再次萃取,合并有机相,静置分液,有机相于45-55℃条件下减压浓缩冷凝管至无大量有机相滴出。反应瓶中加入27mL DCM,滴加入27ml无水乙醇溶解的12.0g马来酸,加毕,常温搅拌反应4-8h,过滤,滤饼于50±5℃条件下真空干燥,收料得14.1g黄色固体,四步反应总收率54.8%。
1HNMR(400MHz,DMSO-d6)δ7.93(s,3H),7.63–7.45(m,2H),7.32(dddd,J=14.9,10.6, 7.9,1.1Hz,3H),7.11(s,1H),6.95(d,J=8.9Hz,1H),6.76(dd,J=2.6,0.8Hz,1H),6.13(s,4H), 4.23–4.02(m,3H),3.77(dd,J=11.8,1.4Hz,1H),2.97(dd,J=12.7,5.0Hz,1H),2.78(dd,J=12.6,7.2Hz,1H)。
(2)中间体M4的制备
在1L单口瓶中依次加入300ml二氯甲烷(5V/M)、60g M3(1.0eq)、200ml纯化水(3.3V/M)开启搅拌,缓慢加入60ml浓氨水(1V/M),反应0.5-1h,静置、分液,有机相加200ml 纯化水(3.3V/M),60ml氨水(1V/M)游离,静置、分液,有机相于45-55℃条件下减压浓缩冷凝管至明显液滴滴出。单口瓶中加入240ml甲苯(4V/M)及60.53g原乙酸三甲酯 (4.5eq.),升温至110℃,反应16-24h,至TLC检测反应完全。反应体系降温至60±5℃,相同温度条件下减压浓缩至冷凝管无大量有机相滴出,加120g甲苯(2V/M)浓缩带水,于 60℃条件下减压浓缩至冷凝管至无明显液滴流出;加入120g甲苯(2V/M)于60℃条件下减压浓缩冷凝管至无大量有机相滴出。反应瓶中加入60-120ml EA(1-2v/m),升温至回流溶清,重结晶,降至室温,搅拌析晶4-6h,过滤,滤饼用60g EA(1V/M)淋洗,于50±5℃条件下真空干燥6-8h,收料得到M4为浅黄色固体39.9g,收率85%,HPLC纯度99.87%。
1HNMR(400MHz,DMSO-d6)δ7.68–7.59(m,2H),7.55(dddd,J=8.4,7.3,5.2,1.9Hz,1H),7.46(d,J=8.4Hz,1H),7.31(td,J=7.6,1.1Hz,1H),7.23(ddd,J=11.4,8.3,1.1Hz,1H), 7.11(d,J=2.5Hz,1H),4.67–4.54(m,1H),3.90–3.77(m,2H),3.70(ddd,J=14.5,7.0,1.5Hz, 1H),1.57(d,J=1.5Hz,3H).
(3)咪达唑仑的制备
2L四口瓶依次加入150ml,二甲基亚砜(10V/M),30g M4(92mmol,1.0eq),23.7gMn02(3.0eq.),升温至150℃,反应1-4h,至TLC检测反应完全。反应体系降至室温,加入300ml 乙酸乙酯,硅藻土垫滤,滤饼用150ml乙酸乙酯淋洗,加入纯化水200ml洗涤,分液。水相用乙酸乙酯萃取两次,每次150ml,合并有机相,150ml饱和氯化钠水溶液洗涤,150ml纯化水洗涤,减压浓缩至无明显液滴流出,得到目标产物成类白色固体,收率76%,HPLC纯度99.89%。
1HNMR(400MHz,DMSO-d6)δ7.91–7.68(m,1H),7.68–7.44(m,1H),7.44–7.10(m,2H),6.90(s,1H),5.10(dd,J=12.8,2.1Hz,1H),4.05(d,J=12.6Hz,1H)。
实施例6咪达唑仑的制备
(1)中间体M3的制备
在实施例4反应完成后体系中加入无水甲醇180ml(3V),分批缓慢加入浓盐酸167ml (10.0eq.)反应约1-3h,至TLC检测反应完全。反应液缓慢加入浓氨水调节PH至10-11,室温搅拌4-6h,TLC检测反应完成后加入饮用水180mL,分液,水相用乙酸乙酯萃取两次,每次600ml,合并有机相,用饱和氯化钠水溶液400ml,洗涤。有机相减压浓缩至无明显液滴流出,加入无水乙醇120ml,乙酸乙酯120ml,加入马来酸47.4g,加毕,常温搅拌4-8h,过滤,干燥,得到产物77.2g。两步总收率90%。
1HNMR(400MHz,DMSO-d6)δ7.93(s,3H),7.63–7.45(m,2H),7.32(dddd,J=14.9,10.6, 7.9,1.1Hz,3H),7.11(s,1H),6.95(d,J=8.9Hz,1H),6.76(dd,J=2.6,0.8Hz,1H),6.13(s,4H), 4.23–4.02(m,3H),3.77(dd,J=11.8,1.4Hz,1H),2.97(dd,J=12.7,5.0Hz,1H),2.78(dd,J=12.6,7.2Hz,1H).
(2)中间体M4的制备
在1L单口瓶中依次加入300ml二氯甲烷(5V/M)、60g M3(1.0eq)、200ml纯化水(3.3V/M)开启搅拌,缓慢加入60ml浓氨水(1V/M),反应0.5-1h,静置、分液,有机相加200ml 纯化水(3.3V/M),60ml氨水(1V/M)游离,静置、分液,有机相于45-55℃条件下减压浓缩冷凝管至明显液滴滴出。单口瓶中加入240ml甲苯(4V/M)及60.53g原乙酸三甲酯 (4.5eq.),升温至110℃,反应16-24h,至TLC检测反应完全。反应体系降温至60±5℃,相同温度条件下减压浓缩至冷凝管无大量有机相滴出,加120g甲苯(2V/M)浓缩带水,于 60℃条件下减压浓缩至冷凝管至无明显液滴流出;加入120g甲苯(2V/M)于60℃条件下减压浓缩冷凝管至无大量有机相滴出。反应瓶中加入60-120ml EA(1-2v/m),升温至回流溶清,重结晶,降至室温,搅拌析晶4-6h,过滤,滤饼用60g EA(1V/M)淋洗,于50±5℃条件下真空干燥6-8h,收料得到M4为浅黄色固体26.08g,收率71.2%,纯度98.95%。
1HNMR(400MHz,DMSO-d6)δ7.68–7.59(m,2H),7.55(dddd,J=8.4,7.3,5.2,1.9Hz,1H),7.46(d,J=8.4Hz,1H),7.31(td,J=7.6,1.1Hz,1H),7.23(ddd,J=11.4,8.3,1.1Hz,1H), 7.11(d,J=2.5Hz,1H),4.67–4.54(m,1H),3.90–3.77(m,2H),3.70(ddd,J=14.5,7.0,1.5Hz, 1H),1.57(d,J=1.5Hz,3H).
(3)咪达唑仑的制备
2L四口瓶依次加入150ml,DMSO(10V/M),30g M4(92mmol,1.0eq),90g MnO2(3.0M),升温至150℃,反应1-4h,至TLC检测反应完全。反应体系降至室温,加入450ml 乙酸乙酯,硅藻土垫滤,滤饼用150ml乙酸乙酯淋洗,加入纯化水300ml洗涤,分液。水相用乙酸乙酯萃取两次,每次150ml,合并有机相,150ml饱和氯化钠水溶液洗涤,150ml纯化水洗涤,减压浓缩至无明显液滴流出。
反应瓶中加入54mL四氢呋喃,加入54mL无水乙醇溶解的马来酸(21.2g,2.0eq.)溶液,搅拌30min,加入130ml甲基叔丁基醚,常温下搅拌过夜,抽滤,滤饼于50±5℃条件下真空干燥6-8h,收料得20.8g浅黄色咪达唑仑马来酸盐固体,纯度96.37%。
在反应瓶中加入20.8g咪达唑仑马来酸盐固体,加入42ml THF,20ml无水乙醇,升温至回流溶清,缓慢降温至5±5℃,缓慢滴入84ml甲基叔丁基醚,搅拌1-3h,过滤收集固体,于50±5℃条件下减压干燥,收料得19.4g精制品。
在反应瓶中依次加入75ml二氯甲烷,15g咪达唑仑马来酸盐,60ml纯化水(4V/M)及30ml浓氨水(2V/M),于室温条件下游离反应1-2h,静置分液,有机相于45-55℃条件下减压浓缩至冷凝管至无大量液滴流出。反应瓶中加入24ml甲醇,加入30ml纯化水,自然降温至5±5℃,析晶2-6h,过滤,滤固体于50±5℃条件下减压干燥,收料得15.5g咪达唑仑,呈白色固体,纯度99.92%,本步骤总收率52%。
1HNMR(400MHz,DMSO-d6)δ7.91–7.68(m,1H),7.68–7.44(m,1H),7.44–7.10(m,2H),6.90(s,1H),5.10(dd,J=12.8,2.1Hz,1H),4.05(d,J=12.6Hz,1H)。
以上所述的实施例仅仅是对本发明的优选实施方式进行描述,并非对本发明的范围进行限定,在不脱离本发明设计精神的前提下,本领域普通技术人员对本发明的技术方案作出的各种变形和改进,均应落入本发明权利要求书确定的保护范围内。
Claims (6)
1.一种中间体M2,
其中,所述X,Y分别独立地选自O或S,n取自1-3;R,R’分别独立地选自烷氧羰基或酰基;所述烷氧羰基为甲氧羰基、乙氧羰基或叔丁氧羰基,酰基为三氟乙酰基。
2.如权利要求1所述中间体M2,其特征在于,所述烷氧羰基为叔丁氧羰基。
3.一种如权利要求1所述中间体M2的制备方法,其特征在于,包括如下步骤:
1)以SM1作为起始物料,与醇、硫醇或者巯基取代的醇生成中间体M1;
2)在反应溶剂中,M1与SM2先形成亚胺,再在还原剂的作用下还原得到中间体M2;
其中,
第1)步所述醇为乙二醇或丙二醇,硫醇为乙二硫醇或丙二硫醇,巯基取代的醇为2-巯基乙醇或2-巯基丙醇;
第2)步所述反应溶剂为甲苯、二甲苯或均三甲苯;第2)步所述SM2为烷氧羰基或酰基保护的1,3-二胺基丙酮,R,R’限定如权利要求1中R,R’的定义;第2)步所述还原剂选自三乙酰氧基硼氢化钠、氰基硼氢化钠或硼氢化钠。
4.一种如权利要求1所述中间体M2的制备方法,其特征在于,包括如下步骤:
1)以SM1作为起始物料,与醇、硫醇或者巯基取代的醇生成中间体M1;
2)在反应溶剂中,M1与SM2在布朗斯特酸及还原剂的作用下,还原胺化得到M2;
其中,
第1)步所述醇为乙二醇或丙二醇,硫醇为乙二硫醇或丙二硫醇,巯基取代的醇为2-巯基乙醇或2-巯基丙醇;
第2)步所述反应溶剂为1,2-二氯乙烷、二氯甲烷、四氢呋喃、乙腈或甲苯;第2)步所述SM2为烷氧羰基或酰基保护的1,3-二胺基丙酮,R,R’限定如权利要求1中R,R’的定义;第2)步所述布朗斯特酸选自醋酸、甲酸、三氟乙酸、草酸、浓盐酸、氢溴酸或浓硫酸;第2)步所述还原剂选自三乙酰氧基硼氢化钠、氰基硼氢化钠或硼氢化钠。
5.一种以M2为中间体制备咪达唑仑的方法,其特征在于,包括如下步骤:
1)中间体M2在布朗斯特酸以及碱的作用下得到M3;
2)M3与原乙酸三甲酯反应得到M4;
3)M4经氧化剂氧化得到咪达唑仑;
第1)步所述布朗斯特酸选自三氟乙酸、盐酸、氢溴酸、硫酸、磷酸或高氯酸;第1)步所述碱选自氨水、三乙胺、二异丙基乙胺、三甲胺、二乙胺或二甲胺;
第3)步所述氧化剂选自二氧化锰和/或二甲基亚砜。
6.一种咪达唑仑的制备方法,其特征在于,包括如下步骤:
1)以SM1作为起始物料,与醇、硫醇或巯基取代的醇生成中间体M1;
2)M1与SM2在布朗斯特酸及还原剂的作用下,还原胺化得到M2;或M1与SM2先形成亚胺,再在还原剂的作用下还原得到中间体M2;
3)中间体M2在布朗斯特酸以及碱的作用下关环得到M3;
4)M3与原乙酸三甲酯反应得到M4;
5)M4经氧化剂氧化得到咪达唑仑;
其中,
第1)步所述醇为乙二醇或丙二醇,硫醇为乙二硫醇或丙二硫醇,巯基取代的醇为2-巯基乙醇或2-巯基丙醇;
第2)步所述反应溶剂为1,2-二氯乙烷、二氯甲烷、四氢呋喃、乙腈或甲苯;第2)步所述SM2为烷氧羰基或酰基保护的1,3-二胺基丙酮,R,R’限定如权利要求1中R,R’的定义;第2)步所述布朗斯特酸选自醋酸、甲酸、三氟乙酸、草酸、浓盐酸、氢溴酸或浓硫酸;第2)步所述还原剂选自三乙酰氧基硼氢化钠、氰基硼氢化钠或硼氢化钠;
第3)步所述布朗斯特酸选自三氟乙酸、盐酸、氢溴酸、硫酸、磷酸或高氯酸;第1)步所述碱选自氨水、三乙胺、二异丙基乙胺、三甲胺、二乙胺或二甲胺;
第5)步所述氧化剂选自二氧化锰和/或二甲基亚砜。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111023875 | 2021-09-02 | ||
CN202111023875X | 2021-09-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114773348A CN114773348A (zh) | 2022-07-22 |
CN114773348B true CN114773348B (zh) | 2024-03-15 |
Family
ID=82409143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210576934.4A Active CN114773348B (zh) | 2021-09-02 | 2022-05-25 | 一种咪达唑仑的制备方法及其中间体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114773348B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115232132B (zh) * | 2022-07-25 | 2024-02-13 | 福安药业集团重庆礼邦药物开发有限公司 | 一种盐酸咪达唑仑g晶型及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106032380A (zh) * | 2015-03-16 | 2016-10-19 | 王志训 | 一种咪达唑仑的工业制造方法 |
CN106032381A (zh) * | 2015-03-16 | 2016-10-19 | 王志训 | 一种咪达唑仑衍生物的工业制造方法 |
-
2022
- 2022-05-25 CN CN202210576934.4A patent/CN114773348B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106032380A (zh) * | 2015-03-16 | 2016-10-19 | 王志训 | 一种咪达唑仑的工业制造方法 |
CN106032381A (zh) * | 2015-03-16 | 2016-10-19 | 王志训 | 一种咪达唑仑衍生物的工业制造方法 |
Also Published As
Publication number | Publication date |
---|---|
CN114773348A (zh) | 2022-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhou et al. | Antitumor agents. 120. New 4-substituted benzylamine and benzyl ether derivatives of 4'-O-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II | |
CN103626766A (zh) | 与取代的杂环稠合的γ-咔啉的合成 | |
CN114773348B (zh) | 一种咪达唑仑的制备方法及其中间体 | |
AU698595B2 (en) | 3-phenylisoquinol-1(2H)-one derivatives, their preparation and their therapeutic application | |
CN102993205B (zh) | 一种高收率制备高纯度西地那非游离碱的纯化方法 | |
CN113024554B (zh) | 一种卢美哌隆中间体的制备方法 | |
CN112110897B (zh) | 一种氘代克里唑蒂尼及其衍生物的制备方法 | |
CN107501196B (zh) | 用于制备地西泮-d5和地西泮-d8的中间体及其制备方法 | |
US7776852B2 (en) | Process for producing highly pure midazolam and salts thereof | |
JP7301858B2 (ja) | トラゾドンの調製のための継続的なプロセス | |
CN105693603A (zh) | 改良的马来酸茚达特罗制备工艺 | |
BR112021011854A2 (pt) | Síntese de gama-carbolinas heterocíclicas fundidas substituídas | |
CN116041222A (zh) | 一种咪达唑仑的制备方法及其中间体 | |
CN117460720A (zh) | 一种杂环烷基类化合物的制备方法、其中间体及其应用 | |
CN112920135A (zh) | 一种盐酸齐拉西酮原料中的二聚体杂质及其制备方法 | |
CN106478506B (zh) | 半水绿卡色林盐酸盐的制备方法 | |
KR900004146B1 (ko) | 아릴 치환된 피리도[1,4]벤조디아제핀의 제조방법 및 그 제조중간체 | |
Wu et al. | Synthesis and biological activities of fluorinated 10-hydroxycamptothecin and SN38 | |
CN111808121A (zh) | 一类含杂原子的新型高b环小檗碱类似物及其c-h活化合成方法 | |
CN109516973A (zh) | 取代嘧啶类化合物、其制备方法及用途 | |
CN114907256B (zh) | 一种盐酸贝尼地平的制备方法 | |
CN104262340A (zh) | 一种他达拉非的制备方法 | |
HRP980429A2 (en) | Crystalline 10,10-bis ((2-fluoro-4-pyridinyl)methyl)-9(10h)-anthracenone and an improved process for preparing the same | |
CN112457243B (zh) | 7-溴-5-甲氧基喹啉的合成方法 | |
CN111269211B (zh) | 一种苯并噻吩衍生物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20231220 Address after: No. 8 Xiyuan Avenue, Pidu District, Chengdu City, Sichuan Province, 611731 Applicant after: Chengdu Easton Biopharmaceuticals Co.,Ltd. Address before: 610200 Chengdu Tianfu international biological city, Chengdu, Sichuan (No. 18, Section 2, biological city middle road, Shuangliu District) Applicant before: Chengdu shuoder Pharmaceutical Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |